Promoter Hypermethylation of ARID1A Gene Is Responsible for Its Low mRNA Expression in Many Invasive Breast Cancers

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Zhang, Xianyu ^a   Sun, Qian ^a   Shan, Ming ^a   Niu, Ming ^a   Liu, Tong ^a   Xia, Bingshu ^a   Liang, Xiaoshuan ^a   Wei, Wei ^a   Sun, Shanshan ^a   Zhang, Youxue ^a   Liu, Xiaolong Sean ^a   Song, Qingbin ^b   Yang, Yanmei ^c   Ma, Yuyan ^c   Liu, Yang ^a   Yang, Long ^d   Ren, Yanlv ^a   Zhang, Guoqiang ^a   Pang, Da ^a,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c Heilongjiang Academy of Forestry Science   (China)

^d Technology Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARID1A GENE; ARTICLE; BREAST; BREAST CARCINOMA; CANCER PATIENT; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; EXON; GENE EXPRESSION; GENE LOSS; GENE MUTATION; GENE PRODUCT; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; METHYLATED DNA IMMUNOPRECIPITATION; MUTATION RATE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; BASE SEQUENCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; METHYLATION; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS;

EID: 84872653446     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053931     Document Type: Article

References (21)

1. Dallas PB, Cheney IW, Liao DW, Bowrin V, Byam W, et al. (1998) p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes. Mol Cell Biol 18: 3596-3603.
2. Dallas PB, Pacchione S, Wilsker D, Bowrin V, Kobayashi R, et al. (2000) The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity. Mol Cell Biol 20: 3137-3146.
3. Decristofaro MF, Betz BL, Rorie CJ, Reisman DN, Wang W, et al. (2001) Characterization of SWI/SNF protein expression in human breast cancer cell lines and other malignancies. J Cell Physiol 186: 136-145.
4. Wang X, Nagl NG Jr, Flowers S, Zweitzig D, Dallas PB, et al. (2004) Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer 112: 636.
5. Luo B, Cheung HW, Subramanian A, Sharifnia T, Okamoto M, et al. (2008) Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A 105: 20380-20385.
6. Nagl NG Jr, Wang X, Patsialou A, Van Scoy M, Moran E, (2007) Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell-cycle control. EMBO J 26: 752-763.
7. Nagl NG Jr, Patsialou A, Haines DS, Dallas PB, Beck GR Jr, et al. (2005) The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest. Cancer Res 65: 9236-9244.
8. Jones S, Wang TL, Shih Ie M, Mao TL, Nakayama K, et al. (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330: 228-231.
9. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, et al. (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543.
10. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, et al. (2012) Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci U S A 109: E252-259.
11. Zhang X, Zhang Y, Yang Y, Niu M, Sun S, et al. (2012) Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance. Cancer Epidemiol 36: 288-293.
12. Mamo A, Cavallone L, Tuzmen S, Chabot C, Ferrario C, et al. (2012) An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene 31: 2090-2100.
13. Cornen S, Adelaide J, Bertucci F, Finetti P, Guille A, et al. (2012) Mutations and deletions of ARID1A in breast tumors. Oncogene.
14. Wiegand KC, Lee AF, Al-Agha OM, Chow C, Kalloger SE, et al. (2011) Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 224: 328-333.
15. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, et al. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44: 694-698.
16. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, et al. (2012) Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 25: 282-288.
17. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, et al. (2012) Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 33: 100-103.
18. Feinberg AP, Tycko B, (2004) The history of cancer epigenetics. Nat Rev Cancer 4: 143-153.
19. Esteller M, (2008) Epigenetics in cancer. N Engl J Med 358: 1148-1159.
20. Tsai HC, Baylin SB, (2011) Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 21: 502-517.
21. Cancer Genome Atlas Research Network, (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.